LY4065967

Phase 1Completed
1 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Healthy

Conditions

Healthy

Trial Timeline

Jun 23, 2025 → Aug 16, 2025

About LY4065967

LY4065967 is a phase 1 stage product being developed by Eli Lilly for Healthy. The current trial status is completed. This product is registered under clinical trial identifier NCT07039045. Target conditions include Healthy.

What happened to similar drugs?

20 of 20 similar drugs in Healthy were approved

Approved (20) Terminated (1) Active (0)

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT07039045Phase 1Completed

Competing Products

20 competing products in Healthy

See all competitors
ProductCompanyStageHype Score
Use of Wearable Digital Sensors After mRNA Vaccination in AdultsModernaPreclinical
0
mRNA-0184ModernaPhase 1
0
mRNA-6231ModernaPhase 1
0
LetrozoleDr. Reddy's LaboratoriesPhase 1
26
IsotretinoinDr. Reddy's LaboratoriesPhase 1
26
FexofenadineDr. Reddy's LaboratoriesPhase 1
26
SertralineDr. Reddy's LaboratoriesPhase 1
26
Nizatidine + AxidDr. Reddy's LaboratoriesPhase 1
26
AnastrozoleDr. Reddy's LaboratoriesPhase 1
26
mRNA-1273.712ModernaApproved
0
RisperidoneDr. Reddy's LaboratoriesPhase 1
26
LamotrigineDr. Reddy's LaboratoriesPhase 1
26
Metformin + GlucophageDr. Reddy's LaboratoriesPhase 1
26
LamotrigineDr. Reddy's LaboratoriesPhase 1
26
mRNA-0184ModernaPhase 1
0
Divalproex SodiumDr. Reddy's LaboratoriesPhase 1
26
SirolimusDr. Reddy's LaboratoriesPhase 1
26
GlimepirideDr. Reddy's LaboratoriesPhase 1
26
Ziprasidone HydrochlorideDr. Reddy's LaboratoriesPhase 1
26
Naproxen sodiumDr. Reddy's LaboratoriesPhase 1
26